ライフサイエンスコーパス: autoimmune disorder

1 n a severe, multi-organ, lymphoproliferative autoimmune disorder.

2 matosus (SLE) is a devastating multisystemic autoimmune disorder.

3 mechanisms responsible for this prototypical autoimmune disorder.

4 myasthenia gravis (MG) is a relatively rare autoimmune disorder.

5 ere were 20 patients (50%) with some form of autoimmune disorder.

6 and factor (VWF) antibody associated with an autoimmune disorder.

7 for an autoantibody-mediated organ-specific autoimmune disorder.

8 chromatin remodeling in curing this complex autoimmune disorder.

9 nd function, leading to a fatal, early-onset autoimmune disorder.

10 central in the pathogenesis of inflammatory autoimmune disorders.

11 vantage than men, yet they are more prone to autoimmune disorders.

12 valuated for the therapy of inflammatory and autoimmune disorders.

13 Rac1-targeting chemotherapeutic agent(s) for autoimmune disorders.

14 lso used to treat several systemic and local autoimmune disorders.

15 ells and may thus contribute to the onset of autoimmune disorders.

16 xacerbate symptoms associated with other CNS autoimmune disorders.

17 CD4(+) T-cells widely implicated in various autoimmune disorders.

18 pe I interferons (IFNs) and in patients with autoimmune disorders.

19 e have been identified as common to multiple autoimmune disorders.

20 ere complication of lupus and other systemic autoimmune disorders.

21 rs for applications as diverse as cancer and autoimmune disorders.

22 ional risk factors, such as individuals with autoimmune disorders.

23 e abnormalities that could increase risk for autoimmune disorders.

24 etic susceptibility to CVID may overlap with autoimmune disorders.

25 for immunomodulatory effects on allergic and autoimmune disorders.

26 y while uncontrolled responses can result in autoimmune disorders.

27 utic candidates for the treatment of various autoimmune disorders.

28 rgeted for the treatment of Th17 cell-driven autoimmune disorders.

29 cts of sunlight UV exposure in patients with autoimmune disorders.

30 polymorphism (SNP) associated with multiple autoimmune disorders.

31 However, overproduction is associated with autoimmune disorders.

32 pathogenesis of multiple sclerosis and other autoimmune disorders.

33 ascular events, and diverse inflammatory and autoimmune disorders.

34 us pathogens and, at the same time, to avoid autoimmune disorders.

35 revention and treatment of CNS-demyelinating autoimmune disorders.

36 he treatment of multiple sclerosis and other autoimmune disorders.

37 jection and type 1 diabetes as well as other autoimmune disorders.

38 auma exposure and PTSD may increase risk for autoimmune disorders.

39 HLA instability mediates the development of autoimmune disorders.

40 cture in major infectious, inflammatory, and autoimmune disorders.

41 the treatment of allergic, inflammatory and autoimmune disorders.

42 se overexpression is associated with several autoimmune disorders.

43 mulatory RNA, with implications for specific autoimmune disorders.

44 nked to the pathogenesis of inflammatory and autoimmune disorders.

45 nisms present in several diseases, including autoimmune disorders.

46 elopment of novel therapeutic strategies for autoimmune disorders.

47 toimmune (type 1) diabetes and certain other autoimmune disorders.

48 It promotes the expansion of Th17 cells in autoimmune disorders.

49 ecessive genetic phenotypes in a spectrum of autoimmune disorders.

50 l Treg cells has been previously reported in autoimmune disorders.

51 tion efficiently silences a variety of human autoimmune disorders.

52 ive disorders, chronic viral infections, and autoimmune disorders.

53 roviding novel information and insights into autoimmune disorders.

54 ence host susceptibility to extra-intestinal autoimmune disorders.

55 to the treatment of multiple T-cell mediated autoimmune disorders.

56 necroptosis may underlie human fibrotic and autoimmune disorders.

57 have important implications for Ab-mediated autoimmune disorders.

58 LYP inhibitors for treating a wide range of autoimmune disorders.

59 and therapeutic target in cardiovascular and autoimmune disorders.

60 munity to certain tumours, tissue grafts, or autoimmune disorders.

61 ng immune complex (IC)-mediated inflammatory/autoimmune disorders.

62 t target adaptive immunity in organ-specific autoimmune disorders.

63 tions and a marked predisposition to develop autoimmune disorders.

64 a loss-of-function variant seems to promote autoimmune disorders.

65 analyzed for anti-nuclear antibodies and for autoimmune disorders.

66 t are also implicated in the pathogenesis of autoimmune disorders.

67 epresent a promising therapeutic approach to autoimmune disorders.

68 l for the immune system and the avoidance of autoimmune disorders.

69 for therapeutic intervention in MS and other autoimmune disorders.

70 c strategy for treatment of B cell dependent autoimmune disorders.

71 on in RA and potentially other Th17-mediated autoimmune disorders.

72 antimicrobial peptides to the development of autoimmune disorders.

73 ic targets for treatment of inflammatory and autoimmune disorders.

74 treatments of cancer, chronic infections, or autoimmune disorders.

75 potential utility for the treatment of human autoimmune disorders.

76 for therapeutic intervention in allergic and autoimmune disorders.

77 ms the basis for allergy, asthma and various autoimmune disorders.

78 ental autoimmune encephalomyelitis and other autoimmune disorders.

79 apies for common diseases such as cancer and autoimmune disorders.

80 sidered a potential therapeutic approach for autoimmune disorders.

81 e treatment of cancer, organ transplant, and autoimmune disorders.

82 stemic lupus erythematosus and several other autoimmune disorders.

83 d polymorphisms in ERAAP are associated with autoimmune disorders.

84 ic targets in malignant, cardiovascular, and autoimmune disorders.

85 vation can cause malignant, inflammatory, or autoimmune disorders.

86 involved in the pathophysiology of multiple autoimmune disorders.

87 robes but also causing tissue destruction in autoimmune disorders.

88 le forms (sTyro3, sAxl, sMer) are related to autoimmune disorders.

89 FNalpha expression that occur during certain autoimmune disorders.

90 cal role of these cells in the regulation of autoimmune disorders.

91 improve the treatment of MS, or indeed other autoimmune disorders.

92 2 C1858T) has been linked to a wide range of autoimmune disorders.

93 lls may be a promising strategy for treating autoimmune disorders.

94 ling, myocardial injury, atherosclerosis and autoimmune disorders.

95 may present a therapeutic strategy for these autoimmune disorders.

96 od-onset interferonopathy and adult systemic autoimmune disorders.

97 l, and/or function in T1D and possibly other autoimmune disorders.

98 function and has been implicated in several autoimmune disorders.

99 peutic potential for Treg-based therapies of autoimmune disorders.

100 s potential in a variety of inflammatory and autoimmune disorders.

101 een linked to immune deficiencies as well as autoimmune disorders.

102 at could be employed to inhibit the ROCKs in autoimmune disorders.

103 t relative hazards were observed in systemic autoimmune disorders (1.32; 95% CI, 1.16-1.50) and syste

104 Autoimmune disorders (24 patients [17%]) and CU (17 pati

105 years; median AMA titer 1:160; extrahepatic autoimmune disorders 46%; normal serum alkaline phosphat

106 ), inflammatory arthritis (27 358), systemic autoimmune disorders (7472), and systemic vasculitis (62

107 mutation carriers have an increased risk of autoimmune disorders, accompanied by elevated levels of

108 he possibility that this disorder or similar autoimmune disorders affecting synaptic proteins, which

109 ive risk (ARR) for diagnosis with any of the autoimmune disorders alone or in combination compared wi

110 However, little is known about the risk for autoimmune disorders among individuals with PTSD.

111 ly suggests a pathogenetic link between this autoimmune disorder and malignant thyroid lymphoma.

112 itical for Treg function, result in a severe autoimmune disorder and the production of various autoan

113 re implicated in cancer and inflammatory and autoimmune disorders and are targets of numerous antagon

114 s become an attractive therapeutic target in autoimmune disorders and B-cell malignancies.

115 , and potent inhibitors for the treatment of autoimmune disorders and cancer.

116 merged as a promising therapeutic target for autoimmune disorders and cancer.

117 eover, B cell misregulation is implicated in autoimmune disorders and cancers such as multiple sclero

118 ingly, TBK1 dysregulation has been linked to autoimmune disorders and cancers, heightening the need t

119 Both are widely used to treat autoimmune disorders and certain cancers.

120 omplicated causes, such as cancer, diabetes, autoimmune disorders and degenerative diseases.

121 as found in the bone marrow of patients with autoimmune disorders and in NPM1-mutated acute myelogeno

122 n occurs with GABAergic and other coexisting autoimmune disorders and is potentially treatable.

123 B cells contribute to multiple aspects of autoimmune disorders and may play a role in triggering d

124 manipulate innate responses for treatment of autoimmune disorders and microbial infection.

125 ing (RBR) E3 ligases have been implicated in autoimmune disorders and neurodegenerative diseases.

126 The initial trigger for both systemic autoimmune disorders and organ-specific autoimmune disor

127 cognized, role for AS in the pathogenesis of autoimmune disorders and particularly for T1D.

128 REX1) is a known DNA exonuclease involved in autoimmune disorders and the antiviral response.

129 ations of psychosis with a family history of autoimmune disorders and vice versa.

130 CD46 deficiency causes an autoimmune disorder, and this protein is also involved i

131 e clinic for treating inflammatory diseases, autoimmune disorders, and hematologic cancers.

132 ples from patients with varied infectious or autoimmune disorders, and in the case of Sjogren's syndr

133 y conditions such as traumatic brain injury, autoimmune disorders, and infections to neuropsychiatric

134 CDDO-DFPA in the treatment and prevention of autoimmune disorders, and its capacity to induce toleran

135 stance and type 2 diabetes, inflammatory and autoimmune disorders, and neurological disorders.

136 Rheumatoid arthritis and other autoimmune disorders are associated with altered activit

137 Several autoimmune disorders are associated with this condition

138 Some autoimmune disorders are monogenetic diseases; however,

139 Infections and autoimmune disorders are more frequent in Down syndrome,

140 portions of patients with NCWS or CD develop autoimmune disorders, are ANA positive, and showed DQ2/D

141 CR, and TLR signals in WAS, and likely other autoimmune disorders, are sufficient to alter B cell tol

142 To make genetic comparisons across autoimmune disorders as informative as possible, a dense

143 ders such as obesity, diabetes mellitus, and autoimmune disorders as well as neuropsychiatric disorde

144 ious immune system genes to common polygenic autoimmune disorders, as well as the pathophysiologic pa

145 Systemic lupus erythematosus is an autoimmune disorder associated with the accumulation of

146 being repositioned to treat inflammatory and autoimmune disorders at lower doses by targeting Tregs.

147 ently published study suggests that NS is an autoimmune disorder based on findings of cross-reacting

148 s with multiple myeloma and B cell-dependent autoimmune disorders but exert toxicity from inhibition

149 as a potential treatment for alloimmune and autoimmune disorders, but it is unknown whether disturba

150 s pathogens contribute to the development of autoimmune disorders, but the mechanisms connecting thes

151 ly unclear if T reg cell deficiency-mediated autoimmune disorders can be treated by targeting the ent

152 d in many pathological conditions, including autoimmune disorders, cancer, and cardiovascular and all

153 is associated with mortality during sepsis, autoimmune disorders, cancer, and diabetes.

154 spectrum of diseases, including infections, autoimmune disorders, cancers, and pregnancy disorders,

155 like cancer, neurodegenerative diseases, or autoimmune disorders, caspases have been intensively inv

156 Brain autoimmune disorder caused accumulation of the ubiquitin

157 evident in the spectrum of inflammatory and autoimmune disorders caused by defects in PS receptors a

158 evident in the spectrum of inflammatory and autoimmune disorders caused by defects in these pathways

159 Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by a breakdown of self

160 Neuromyelitis optica is a rare neurological autoimmune disorder characterized by a poor prognosis.

161 with systemic lupus erythematosus (SLE), an autoimmune disorder characterized by autoantibody produc

162 mmune disease, is a debilitating multisystem autoimmune disorder characterized by chronic inflammatio

163 didiasis ectodermal dystrophy (APECED) is an autoimmune disorder characterized by chronic mucocutaneo

164 Systemic sclerosis (SSc) is an autoimmune disorder characterized by fibrosis of the ski

165 IgG4-RD is a multiorgan autoimmune disorder characterized by fibrous inflammatio

166 te receptor (NMDAR) encephalitis is a severe autoimmune disorder characterized by high intrathecal an

167 Primary Sjogren syndrome (pSS) is an autoimmune disorder characterized by ocular and oral dry

168 ntiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent thrombosi

169 Rheumatoid arthritis is an autoimmune disorder characterized by T cell dysregulatio

170 Sarcoidosis is a presumptive autoimmune disorder characterized by the presence of non

171 Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by the production of a

172 Celiac disease (CD) is an autoimmune disorder, characterized by the presence of ga

173 hus represent a viable therapeutic target in autoimmune disorders, chronic infections and cancers.

174 ions in host defense and in the pathology of autoimmune disorders, chronic inflammatory diseases, and

175 There was a significantly increased risk of autoimmune disorders clustered around inflammatory arthr

176 lls; antibodies, autoantibodies and comorbid autoimmune disorders; complement; oxidative stress; imag

177 proposed to be highly pathogenic in several autoimmune disorders due in part to their expression of

178 s among populations is well-characterized in autoimmune disorders (e.g., rheumatoid arthritis), but t

179 elicobacter pylori, pneumonia) diseases, and autoimmune disorders (e.g., systemic lupus erythematosus

180 sk for autoimmune endocrinopathies and other autoimmune disorders, encode unstable proteins, whereas

181 ten arises in the presence of complications (autoimmune disorders, fractures, and finally, malignancy

182 uromyotonia is increasingly recognized as an autoimmune disorder, frequently associated with antibodi

183 ent conducted with MSCs from a donor with an autoimmune disorder had no positive effects on transplan

184 ly understood, but the occurrence of several autoimmune disorders has been found to vary along a Nort

185 rculating self-reactive IgE in patients with autoimmune disorders has been long known but, at the sam

186 GWAS studies of autoimmune disorders have yielded hundreds of replicated

187 ematosus (SLE), the two most common systemic autoimmune disorders, have both unique and overlapping m

188 esent an alternative approach for therapy of autoimmune disorders; however, dietary antioxidants are

189 e strongly associated with susceptibility to autoimmune disorders; however, it is not clear how genet

190 A large proportion of patients showed autoimmune disorders, i.e. autoimmune thyroiditis (26.3%

191 and genetic association is a risk factor for autoimmune disorders implies an important role for LRRK2

192 lleagues characterized a seemingly monogenic autoimmune disorder in a family that was linked to homoz

193 T cells, which suppresses the development of autoimmune disorder in syngeneic BMTs.

194 =2) each occurring in more than one patient (autoimmune disorder in two patients at 10 mg/kg and one

195 mbert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder in which a significant fraction of t

196 Immune thrombocytopenia (ITP) is an autoimmune disorder in which impaired mesenchymal stem c

197 nti-NMDA receptor (NMDAR) encephalitis is an autoimmune disorder in which the use of immunotherapy an

198 The prevalence of autoimmune disorders in affluent countries has reached e

199 lvement, and higher prevalence of coexisting autoimmune disorders in AQP4-Ab-positive cases.

200 s effector mechanisms results in allergic or autoimmune disorders in genetically predisposed subjects

201 also prevents the initiation of Th1-mediated autoimmune disorders in mice through the suppression of

202 shows that chronic systemic inflammation and autoimmune disorders in the TKO mice cause neuronal dama

203 (CP) of complement is often associated with autoimmune disorders in which disease pathology is linke

204 erapeutic target for CD or potentially other autoimmune disorders in which NKG2D has been implicated.

205 bition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined populatio

206 f the major genetic risk factors for several autoimmune disorders including type 1 diabetes (T1D) in

207 IFIH1 has been linked to a number of autoimmune disorders, including Aicardi-Goutieres syndro

208 ia (CSU) are widely held to often have other autoimmune disorders, including autoimmune thyroid disea

209 aware of the possibility of anti-TNF-induced autoimmune disorders, including DM.

210 e nature of microbial involvement in complex autoimmune disorders, including human autoimmune polygla

211 substantial promise as a treatment for human autoimmune disorders, including inflammatory bowel disea

212 as an inflammation mediator in a variety of autoimmune disorders, including inflammatory bowel disea

213 tential immune-stimulating factor in several autoimmune disorders, including MS and its animal model

214 in diseased tissues of patients with various autoimmune disorders, including multiple sclerosis (MS).

215 e in the susceptibility and severity of many autoimmune disorders, including multiple sclerosis (MS).

216 ributing factors to the pathogenesis of many autoimmune disorders, including multiple sclerosis.

217 JAK inhibitors hold promise for treatment of autoimmune disorders, including rheumatoid arthritis, in

218 lay a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, sy

219 ession will provide new treatment options in autoimmune disorders, including SLE.

220 ry sexual trauma exposure increased risk for autoimmune disorders, including thyroiditis, inflammator

221 Treg insufficiency can lead to autoimmune disorders, including type 1 diabetes (T1D).

222 rategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejectio

223 The relationship between allergy and autoimmune disorders is complex and poorly understood.

224 limumab therapy in patients with preexisting autoimmune disorders is not known.

225 r, their use is generally discouraged in the autoimmune disorder known as immune thrombocytopenia (IT

226 matosus (SLE) is a chronic, life-threatening autoimmune disorder, leading to multiple organ pathologi

227 ng a previously reported type 1 diabetes and autoimmune disorder locus.

228 ht trigger or exacerbate the symptoms of the autoimmune disorder lupus erythematosus is not known but

229 e was performed on the use of AIT in asthma, autoimmune disorders, malignant neoplasias, cardiovascul

230 A synthetase (TARS) is an autoantigen in the autoimmune disorder myositis, and borrelidin, a potent i

231 occurred in nine (17%) of 53 patients, with autoimmune disorder (n=3), increased blood creatine phos

232 s experienced recurrence of their underlying autoimmune disorders, none of the chimeric subjects have

233 Autoimmune disorders occur when the immune system abnorm

234 Myasthenia gravis (MG), an autoimmune disorder of neuromuscular transmission, is tr

235 pathogenesis of multiple sclerosis (MS), an autoimmune disorder of the CNS and thus analyzed the mic

236 Rasmussen encephalitis, a CTL-mediated human autoimmune disorder of the CNS.

237 Celiac disease (CD) is an autoimmune disorder of the small intestine which is trig

238 Systemic sclerosis (SSc) is a polygenic, autoimmune disorder of unknown etiology, characterized b

239 Autoimmune disorders of the CNS have complex pathogenese

240 ential therapeutic intervention for managing autoimmune disorders of the CNS.

241 patients treated at 10 mg/kg dose level, and autoimmune disorder (one [5%]), increased amylase (one [

242 IS/MS in relapse than of those with systemic autoimmune disorders or controls with noninflammatory di

243 essure fluctuations, use of cytotoxic drugs, autoimmune disorders, or eclampsia.

244 Similar HLA changes have been linked to autoimmune disorders, particularly antiphospholipid synd

245 Individuals suffering from autoimmune disorders possess a hyperactive cellular phen

246 mmune-related genes, B3GNT2 is implicated in autoimmune disorders previously tied to schizophrenia ri

247 emic autoimmune disorders and organ-specific autoimmune disorders probably involves the recognition o

248 ne deiminase 4 (PAD4) and that patients with autoimmune disorders produce autoantibodies that recogni

249 However, the direct role of hCMV in inducing autoimmune disorders remains unclear.

250 insulin deficiency, is considered a chronic autoimmune disorder resulting from the destruction of in

251 Rheumatoid arthritis is a chronic autoimmune disorder resulting in synovial inflammation.

252 ere, we provide evidence that for six common autoimmune disorders (rheumatoid arthritis, Crohn's dise

253 8 patients with neurodegenerative, sleep, or autoimmune disorders served as control samples.

254 f symptoms probably indicative of coexisting autoimmune disorders: six had encephalitis with seizures

255 rovide benefit to patients with inflammatory autoimmune disorders such as Crohn's disease, rheumatoid

256 ll differentiation and have implications for autoimmune disorders such as multiple sclerosis.

257 Da RNA-binding protein and an autoantigen in autoimmune disorders such as systemic lupus erythematosu

258 RCA may be associated with collagen vascular/autoimmune disorders such as systemic lupus erythematosu

259 gested to play a role in the pathogenesis of autoimmune disorders such as type 1 diabetes.

260 xp3(+) CD25(+) CD4(+) Treg cells and inhibit autoimmune disorders such as type 1 diabetes.

261 rrant activity is also implicated in several autoimmune disorders, such as Sjogren syndrome.

262 , is also associated with haematological and autoimmune disorders, suggesting that it influences canc

263 nce in mouse models of T1D, as well as other autoimmune disorders, suggests that there are defects in

264 opathy that phenotypically overlaps with the autoimmune disorder systemic lupus erythematosus.

265 diagnoses included nutritional deficiencies, autoimmune disorders, systemic malignancies, and intracr

266 arcolepsy with cataplexy is thought to be an autoimmune disorder targeting hypothalamic hypocretin ne

267 have been observed in multiple sclerosis, an autoimmune disorder that affects the CNS.

268 Rheumatoid arthritis is an autoimmune disorder that affects the joints and other or

269 Graves' disease is an autoimmune disorder that causes hyperthyroidism because

270 Systemic sclerosis (SSc) is an autoimmune disorder that involves skin and internal orga

271 Type 1 diabetes is an autoimmune disorder that is characterized by a failure o

272 Primary acquired PRCA is an autoimmune disorder that is frequently antibody-mediated

273 Celiac disease is an autoimmune disorder that is induced by dietary gluten in

274 Myasthenia gravis is an autoimmune disorder that selectively targets neuromuscul

275 r (NMDAR) encephalitis is a newly identified autoimmune disorder that targets NMDARs, causing severe

276 Sjogren's syndrome (SS) is a chronic autoimmune disorder that typically affects exocrine glan

277 phigoid diseases are a group of well defined autoimmune disorders that are characterised by autoantib

278 ement functions occur in many infectious and autoimmune disorders that have been linked to schizophre

279 tivating mutations in STAT3 with early-onset autoimmune disorders that include diabetes of autoimmune

280 toreactive clones among CD21(low) B cells in autoimmune disorders, the dominant role of SYK in CD21(l

281 ave been reported to be important players in autoimmune disorders, this is the first report pointing

282 thase for the initiation of self-DNA-induced autoimmune disorders, thus providing important implicati

283 paB signaling is implicated in diseases from autoimmune disorders to cancer.

284 Celiac disease is an autoimmune disorder triggered by gluten in genetically p

285 d a serious treatment-related adverse event: autoimmune disorder (two [13%]), lower abdominal pain (o

286 Six patients had 1 or more coexisting autoimmune disorders: type 1 diabetes mellitus (n = 4),

287 hypertension, cancer, or immunodeficiency or autoimmune disorders), use of potential immunomodulators

288 ude of the PTSD-related increase in risk for autoimmune disorders was similar in women and men, and m

289 alarial drugs (AMDs) on clinical features of autoimmune disorders were discovered by chance during Wo

290 , FcRn can contribute to the pathogenesis of autoimmune disorders when an abnormal immune response ta

291 Multiple sclerosis (MS) is an autoimmune disorder where T cells attack neurons in the

292 eptor encephalitis is a severe but treatable autoimmune disorder which diagnosis depends on sensitive

293 n is frequently associated with extrahepatic autoimmune disorders while interferon (IFN) and ribaviri

294 ients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academ

295 tients with systemic lupus erythematosus, an autoimmune disorder with a strong female bias, and obser

296 matosus (SLE) is a type I IFN (IFN-I)-driven autoimmune disorder with exaggerated B and Th cell respo

297 Antiphospholipid syndrome (APS) is an autoimmune disorder with increased risk for thrombosis a

298 trongly involved in several inflammatory and autoimmune disorders with both pro- and anti-inflammator

299 alpha blockade may have therapeutic value in autoimmune disorders with DN T cell expansion.

300 the pathogenesis of several T cell-mediated autoimmune disorders, with molecular mimicry a likely me